Victory Capital Management Inc. Grows Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Victory Capital Management Inc. grew its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 121.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 346,358 shares of the company's stock after buying an additional 190,092 shares during the period. Victory Capital Management Inc. owned approximately 0.77% of Apogee Therapeutics worth $20,345,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Apogee Therapeutics by 21.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company's stock valued at $94,000 after buying an additional 285 shares in the last quarter. EntryPoint Capital LLC raised its stake in shares of Apogee Therapeutics by 44.7% during the first quarter. EntryPoint Capital LLC now owns 1,997 shares of the company's stock worth $133,000 after acquiring an additional 617 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of Apogee Therapeutics in the 2nd quarter worth approximately $143,000. Kennedy Capital Management LLC purchased a new stake in shares of Apogee Therapeutics in the 1st quarter valued at $212,000. Finally, Arizona State Retirement System grew its holdings in shares of Apogee Therapeutics by 4.5% during the 2nd quarter. Arizona State Retirement System now owns 5,993 shares of the company's stock valued at $236,000 after purchasing an additional 258 shares during the last quarter. Institutional investors own 79.04% of the company's stock.

Apogee Therapeutics Price Performance

Shares of APGE stock traded up $1.19 during mid-day trading on Tuesday, reaching $46.52. The stock had a trading volume of 341,082 shares, compared to its average volume of 494,300. The stock's 50-day moving average price is $54.74 and its two-hundred day moving average price is $48.93. Apogee Therapeutics, Inc. has a 52-week low of $16.39 and a 52-week high of $72.29.

Analysts Set New Price Targets

Separately, Wedbush reissued an "outperform" rating and issued a $87.00 price target on shares of Apogee Therapeutics in a research note on Tuesday, November 12th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Apogee Therapeutics has a consensus rating of "Buy" and an average price target of $78.50.

Insider Transactions at Apogee Therapeutics

In related news, CEO Michael Thomas Henderson sold 40,000 shares of the company's stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $47.62, for a total value of $1,904,800.00. Following the sale, the chief executive officer now directly owns 1,394,487 shares of the company's stock, valued at $66,405,470.94. This represents a 2.79 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Jane Henderson sold 6,000 shares of the stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $48.26, for a total value of $289,560.00. Following the completion of the transaction, the chief financial officer now owns 200,871 shares of the company's stock, valued at approximately $9,694,034.46. This trade represents a 2.90 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 120,995 shares of company stock worth $6,417,855. 36.10% of the stock is currently owned by insiders.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.